

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

76
PATENTS
 AND PATENTS PENDING

BIOFILMS are estimated to be responsible for 80% of all human and animal bacterial infections, costing billions of dollars each year.

These higher order structures form matrixes that attach and grow on living or non-living surfaces and can become 1000x more resistant to antibiotics, antimicrobials, biocides, and disinfectants.

This resiliency contributes to numerous human and animal health related problems such as wound care infections, recurrent urinary tract infections, tooth decay, medical device associated and hospital-acquired infections, as well as foodborne bacterial infections.

MISSION

Kane Biotech’s mission is to be a royalty based revenue company licensing its anti-biofilm technologies to global industry players, first in the companion pet animal health market followed by the human health market.

COMMERCIALIZATION STRATEGY

Kane Biotech is now focused on commercialization as opposed to just R & D. We’ve developed a 4 Step approach to our commercialization strategy through which we have successfully implemented our first market opportunity within the North American veterinary channel.

STEP 1 - Canada Used as a Test Market
StrixNB products scientifically formulated with supporting safety and efficacy based on data from third party clinical trials
Branding, premium packaging and positioning, advertising campaign, and veterinary endorsements secured
STEP 2 - Seek Market Access Partner
10+ year royalty agreement negotiated and signed with major veterinary market player
STEP 3 - Build on Milestone/Royalty Payments Through Geographic Expansion
Discussion in progress for expansion to Europe, Asia, ROW
STEP 4 - Seek Additional Partners
Discussion in progress with major player in Pet Specialty, Grooming, Grocery/Mass markets

Listing: TSX Venture Exchange
Stock Symbol: KNE

Listing: OTCQB
Stock Symbol: KNBIF

“In work described in Antimicrobial Agents and Chemotherapy and the Journal of Industrial Microbiology and Biotechnology, researchers at Kane Biotech made therapeutic and analytical progress against biofilms, a particularly intractable form of bacterial growth.”

– Drug Discovery News.com

CONTACT INFORMATION:

Mark Ahrens-Townsend
 President and CEO
 1 204 477 7592
 mahrens-townsend@kanebiotech.com
www.kanebiotech.com

PRODUCTS IN THE MARKET

- Periodontal disease is the #1 disease in dogs and cats. The overall pet healthcare industry in the U.S. is valued at an estimated \$69 billion USD in 2017*
- Kane Biotech launched innovative pet oral care products under the brand names **bluestem™ oral care** (pet specialty channel) and **StrixNB®** (vet channel)



PRODUCTS/TECHNOLOGIES IN DEVELOPMENT

- Wound care products using the patented technology **DispersinB®** are in development. The global market for wound care is \$17 billion USD (2016)**
- Ear infections are one of the most common reasons dogs are taken to the vet. Products in development include otic (ear) drops to break up biofilm in dogs' and cats' ears
- **Alosera™** shampoo for dogs, cats and horses works against atopic dermatitis bacteria and fungi by attacking biofilms, thereby altering the environment they live in so they are relatively easy to kill in their free-floating state
- Shampoos and skin care formulations for skin conditions such as chronic dandruff, seborrheic dermatitis, athlete's foot and atopic dermatitis for humans are in development
- **Aledex®** technology provides a broad-spectrum antibiofilm and antimicrobial activity in medical device coating applications. Excellent data demonstrates the product's ability to inhibit numerous catheter associated pathogens, and protect against infections
- **KBI Hard Surface Disinfectant** disrupts the biofilm environment where bacteria live on hard metal and plastic surfaces and assures the embedded bacteria are killed

FINANCIAL DATA

Share Structure	
Common Shares	80,113,536
Outstanding Options	3,386,000
Common Stock Warrants	35,304,997
Fully Diluted Shares	118,804,533
Board and Management Holdings	
	31.9%
Share Trading Activity	
1 month average daily volume (shares)	9,266
52 week low/high (\$/share)	\$0.08 / \$0.23
Share Price	\$0.14
Weighted Average Option/Warrant Exercise Price	\$0.20
Market Capitalization	
	\$11.2 Million
Cash Balance	
	\$2.5 Million
Debt	
	\$0.00

(all amounts as of September 30, 2017)

* APPA. www.americanpetproducts.org/press_industrytrends.asp

**Markets and Markets. www.marketsandmarkets.com/Market-Reports/wound-care-market-371.html

RECENT MILESTONES

- Signed exclusive licensing and distribution agreement with Dechra Veterinary Products LLC for the North American veterinary market (March 5, 2017).
- Eleven new patents issued, another three imminent.

"For the first time in decades, this person shows NO signs of dandruff at all. I would characterize this result as miraculous! This person has literally tried any and all products including prescription medications. This product you have developed is a GAMECHANGER."

– **Managing Director, Large Investment Banking Firm (Toronto)**

MANAGEMENT TEAM

Mark Ahrens-Townsend
President and CEO

Ray Dupuis
Chief Financial Officer

Grant Humphrey
VP Sales

Dr. Nanda Yakandawala
Senior Research Scientist

Wendy Nachtigall
Director, Marketing

Andrea Gordon
Director, Regulatory and Quality Control